Publication | Closed Access

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Hematological MalignancyOral Fixed-dose CombinationPharmacologyHematologyPharmacotherapyMedicinePhase 1Myelodysplastic SyndromesMyeloid Neoplasia